Home » Clinical Trials » Solid tumors » NCT04550663
NCT04550663

One-center, Open-label, Single-arm Clinical Study of the Safety and Effectiveness of NKG2D CAR-T Cells Infusion in the Treatment of Relapsed/ Refractory NKG2DL+ Tumors

Study Summary

This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.

Want to learn more about this trial?

Request More Info

Interventions

KD-025 CAR-T cellsDRUG
Autologous genetically modified anti-NKG2DLs CAR transduced T cells

Study Locations

FacilityCityStateCountry
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNanjingJiangsuChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026